85results about How to "Improve heart function" patented technology

The invention discloses application of an AXL inhibitor in preparation of a medicine for treating heart failure, and relates to the field of pharmacy. The invention provides application of an AXL inhibitor in a medicine for treating heart failure. The AXL inhibitor can remarkably inhibit abnormal activation of fibroblasts and can remarkably improve the heart function of a mouse with heart failure.

The invention discloses application of an RNF130 activator in preparation of a medicine for preventing and / or treating ischemic heart disease, and belongs to the technical field of biological medicine. Research results show that when an RNF130 activator is given in a mouse of a myocardial ischemia reperfusion injury model, the left ventricular ejection fraction and the left ventricular short-axis shortening rate of the mouse can be improved, myocardial tissue pathological injury can be relieved, the protein expression levels of NOX-2, BAX and TNF-alpha are reduced, the myocardial infarction area is reduced, and myocardial cell apoptosis is reduced; therefore, the RNF130 activator has prevention and treatment effects on the myocardial ischemia-reperfusion injury, that is, the RNF130 activator can be used as an effective component of the medicine for preventing or treating diabetes complicated by myocardial ischemia-reperfusion injury, and a new strategy is provided for preparation of the medicine for preventing and treating myocardial ischemia-reperfusion injury.

The invention discloses application of chrysin-7-0-beta-D-glucuronide in treatment of ischemic heart disease or an LRP6 inhibitor, and belongs to the technical field of treatment of ischemic heart disease. The invention provides a new application of a small molecular compound chrysin-7-0-beta-D-glucuronide, the compound realizes regulation and control on a cardiac muscle cell cycle by inhibiting LRP6, and finally promotes repair of cardiac muscle cells and inhibits apoptosis. According to the invention, by exploring the function of inhibiting LRP6 protein of a small molecule drug, a powerful repair reaction is guided after myocardial ischemia reperfusion, so that effective treatment of myocardial infarction is realized. Therefore, finding of an LRP6 inhibitor not only has a potential curative effect on promoting myocardial cells to enter a cell cycle, but also has important significance on treatment of MI.

The invention discloses bioactive polypeptide hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biomedicine. The antioxidant peptide MMP12 synthesized by the invention is used for removing ROS (reactive oxygen species) in an MI region, so that myocardial cells are protected; the invention relates to an angiogenic peptide KRX, which is used for treating myocardial ischemia during myocardial infarction. Experimental results show that the bioactive polypeptide hydrogel prepared by the invention not only has the functions of resisting oxidation and promoting angiogenesis, but also has obvious effects of resisting apoptosis, resisting inflammation and inhibiting myocardial fibrosis through the combination of the two polypeptides, and the effects can obviously improve the cardiac function, promote the repair of damaged myocardial tissues and improve the cardiac function. The ventricular wall remodeling is inhibited, and a feasible treatment scheme is provided for myocardial infarction treatment.

The invention discloses an application of rilpivirine (RPV) in preparation of a medicine for treating myocardial infarction, and relates to the field of medicines for treating myocardial infarction. The invention belongs to the technical field of biological medicine. According to the present invention, the acute myocardial infarction (AMI) disease mouse model is constructed through the induction of the permanent ligation of the left anterior descending branch; after rilpivirine is orally taken, the conditions of survival, heart function, structure change and the like of the AMI mouse model during X weeks after operation are observed. Results show that rilpivirine (as shown in the formula I) has the effects of remarkably improving the cardiac function of AMI injury, relieving cardiac remodeling and increasing the survival rate of AMI mice. Therefore, a new technical means is provided for treatment of myocardial infarction, and rilpivirine has a wide application prospect in treatment of myocardial infarction diseases. # imgabs0 #

The invention belongs to the technical field of preparation of nano functional materials, and provides a difunctional nanosheet as well as a preparation method and application thereof. On the basis of two-dimensional layered double-metal oxides (LDHs), magnesium-aluminum hydrotalcite (MgAl-LDH) is prepared as a main body laminate, and bioactive components Ce < 3 + > and Sr < 2 + > are introduced into the main body laminate, so that the bifunctional nanosheet capable of accurately and efficiently removing ROS and promoting angiogenesis is developed; wherein due to the existence of Ce < 3 + > and Sr < 2 + >, the nano-sheet has the activity of superoxide dismutase and the characteristic of promoting vascular regeneration at the same time, active sites fully exposed on the surface of the nano-sheet can effectively remove ROS and regulate an anoxic microenvironment, meanwhile, the nano-sheet responds to an ischemic acid microenvironment to release Sr < 2 + >, proliferation and migration of endothelial cells are promoted, and angiogenesis is facilitated. The MgSrCeAl-LDH nanosheet disclosed by the invention is used for treating the MIRI, and the treatment effect is remarkable.

The invention belongs to the field of biological medicine, and particularly relates to application of forsythiaside A in preparation of a medicine for relieving or treating diabetic cardiomyopathy. The forsythiaside A relieves or treats diabetic cardiomyopathy by regulating NLRP3 activation induced by endoplasmic reticulum stress. The forsythiaside A can reduce the levels of BG, GSP, TG, LDH, CK-MB, cTnI, MDA, IL-1beta, IL-6 and TNF-alpha of STZ induced diabetic mice, and meanwhile, the levels of IN and SOD are increased. The forsythiaside A can be used for reducing the expression levels of IL-1beta, IL-6, TNF-alpha, GRP78, TXNIP and NLRP3 in H9c2 cells induced by Glu. Therefore, forsythiaside A can induce NLRP3 inflammasome activation through endoplasmic reticulum stress to relieve diabetic cardiomyopathy, and a theoretical basis is provided for treating diabetic cardiomyopathy.

The invention discloses application of 2-ME in preparation of a medicine for preventing or treating sepsis cardiomyopathy, low-dose 2-ME can recover the activity of myocardial cells damaged by sepsis, reduce the apoptosis rate of the myocardial cells and enhance the contractility of the myocardial cells, so that the heart function is improved; the 2-ME can significantly inhibit cell death, reduce accumulation of disulphide in cells and prevent occurrence of disulphide death, and has potential application prospects in myocardial protection and prevention and treatment of sepsis myocardial injury.

The invention provides a preparation method of a mesenchymal stem cell exosome incubated by a GLP-1 medicine. The preparation method comprises the following steps: S1, preparing materials; s2, separating the human adipose tissue-derived stromal cells; s3, cell surface marker protein detection; s4, carrying out GLP-1 incubation; and S5, extracting the exosome. According to the preparation method of the mesenchymal stem cell exosome incubated with the GLP-1 medicine, the human adipose tissue-derived stromal cell exosome is collected in a specific mode, the whole process is simple and convenient, the obtained human adipose tissue-derived stromal cell exosome is stable in effect, damage of myocardial cells after myocardial infarction can be effectively relieved, the heart function can be enhanced, and the human adipose tissue-derived stromal cell exosome can be used for treating myocardial infarction. The compensatory cardiac machine load is reduced, and the heart failure is relieved.

The invention discloses 4-octyl itaconic acid liposome loaded nano-particles wrapped by a metal-phenolic aldehyde network coating. The nano-particles are used for adjusting a myocarditis microenvironment after acute myocardial infarction. The drug-loaded nanoparticle provided by the invention can be divided into a drug-loaded liposome inner core and a shell layer; the inner core is functionalized liposome nanoparticles loaded with 4-octyl itaconic acid, and the shell layer is a metal-phenolic network coating formed by self-assembly of tannic acid and Mn < 2 + >. The invention further provides application of the drug-loaded nanoparticles in preparation of drugs for treating inflammation causing myocardial injury. The tannic acid of the shell layer of the drug-loaded nanoparticle has high affinity to an extracellular matrix of cardiac muscle tissue, and the drug-loaded nanoparticle injected from caudal vein can be efficiently enriched to a myocardial injury area to play roles in inhibiting pyroptosis of cardiac muscle cells, regulating macrophage functions and remodeling a damaged myocarditis microenvironment; accurate, effective and safe acute myocardial infarction treatment is achieved.

The invention discloses a Dai medicine composition as well as a preparation method and application thereof, and belongs to the technical field of medicines. The Dai medicine composition comprises the following raw materials in parts by weight: 10-20 parts of a turmeric extract and 10-20 parts of amomum tsao-ko essential oil, the turmeric extract is an alcohol extract of turmeric, and the content of sweet myrrh curcumol in the turmeric extract is 5-10 wt.%. The invention discloses application of the Dai medicine composition in preparation of a medicine for preventing or / and treating acute myocardial infarction. The acute myocardial infarction comprises acute myocardial infarction under the condition of non-alcoholic fatty liver. Based on the Yaojiao theory of Dai medicine, the turmeric extract and the amomum tsao-ko essential oil are creatively matched, and the turmeric extract and the amomum tsao-ko essential oil are combined to supplement soil to achieve the effects of leveling four towers, clearing away fire and toxic materials and promoting blood circulation and ventilating. Tests show that the composition disclosed by the invention can relieve liver injury caused by non-alcoholic fatty liver disease, effectively inhibit left ventricular remodeling, improve cardiac functions and reduce acute myocardial infarction of mice under the condition of NAFLD (non-alcoholic fatty liver disease).

The invention discloses a preparation method of a self-oxygen-supply composite nano-carrier applicable to cardiovascular diseases such as myocardial infarction, which comprises the following steps: slowly dripping a potassium permanganate solution into an INN (at) Alb nano-system to promote MnO2 to deposit on the surface of the INN (at) Alb nano-system to prepare a double-layer nano-shell (MnO2 (at) INN (at) Alb), and modifying PEG-2000 on the surface of the double-layer nano-shell to obtain the self-oxygen-supply composite nano-carrier. The obtained self-oxygen-supply composite nano-carrier MnO2 (at) INN (at) Alb can utilize MnO2 to catalyze H2O2 in a myocardial infarction region so as to slowly generate oxygen and reverse a local hypoxic microenvironment of the infarction region, meanwhile, a main drug glibenclamide is slowly released, and the purposes of reducing oxidative stress of myocardial cells, reducing the cell death rate, improving myocarditis and fibrosis and finally improving the heart function are achieved. The pharmaceutical composition can be applied to treatment of cardiovascular diseases such as myocardial infarction, and a new treatment thought is provided for patients with cardiovascular diseases.

An object is to provide a pharmaceutical composition that improves cardiac function when administered during coronary artery bypass surgery for ischemic cardiomyopathy. A pharmaceutical composition for improving cardiac function comprising: (A) a release formulation comprising at least poly(lactic-co-glycolic acid) (PLGA) and a prostaglandin I2 receptor agonist, the PLGA having an average molecular weight of 10000 to 30000; and (B) a release formulation comprising at least poly(lactic-co-glycolic acid) (PLGA) and a prostaglandin I2 receptor agonist, the PLGA having an average molecular weight of 40000 to 60000.

The invention discloses a traditional Chinese medicine composition for improving heart and kidney function decline and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 20-40 parts of ginseng, 20-40 parts of rabdosia rubescens, 10-30 parts of pseudo-ginseng, 5-25 parts of glossy privet fruit, 5-25 parts of schisandra chinensis and 5-25 parts of cinnamon; the invention further discloses a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition has the beneficial effects that ginseng is used as a monarch drug to tonify qi, tonify heart and enhance cardiac contractility, which is a leading drug of the whole formula; rabdosia rubescens and pseudo-ginseng serve as ministerial drugs, rabdosia rubescens can clear away heat and toxic materials, pseudo-ginseng can promote blood circulation to remove blood stasis, and the ministerial drugs jointly assist the And glossy privet fruit, schisandra chinensis and cinnamon are used as adjuvant drugs to nourish liver and kidney, astringe and induce astringency, warm yang and dredge vessels, and promote the exertion of the efficacy of the whole prescription. All the medicines are combined to comprehensively regulate heart and kidney functions and improve the living quality of patients.

The invention belongs to the technical field of medicine application, and relates to application of a composition in preparation of a medicine for treating unstable angina pectoris, the composition and combined use of the composition and nicodil are used for improving the attack frequency of the unstable angina pectoris and the lasting time of the unstable angina pectoris, reducing the levels of LDL-C, TC and TG in serum, and improving the treatment effect of the unstable angina pectoris. According to the present invention, the application of the preparation of the unstable angina pectoris treatment drug can be provided, such that the HDL-C level in the serum can be increased, the BNP level and the LVEDD level in the plasma can be reduced, and the LVEF level can be increased; the composition disclosed by the invention and the combination of the composition and nicodil can improve the attack frequency of unstable angina pectoris, shorten the symptom duration and improve the effective rate of treatment.

The invention relates to a drug delivery system, and discloses a bionic traditional Chinese medicine co-assembled drug delivery system targeting myocardial fibrosis and application of the bionic traditional Chinese medicine co-assembled drug delivery system. The bionic traditional Chinese medicine co-assembled drug delivery system is mainly formed by wrapping traditional Chinese medicine co-assembled nanoparticles with a platelet membrane; the traditional Chinese medicine co-assembled nanoparticle is composed of a natural small molecule compound astragaloside derivative LS102 and Z-ligustilide, the preparation process is simple, no carrier is needed, and the cost is low. According to the bionic traditional Chinese medicine co-assembled nano drug delivery system, the particle size distribution is 190-200 nm, the potential is about-30 mV, and the bionic traditional Chinese medicine co-assembled nano drug delivery system is in a uniform sphere shape of a core-shell structure and is high in stability and biological safety. According to the invention, the blood vessel injury diseases such as myocardial infarction, myocardial fibrosis, atherosclerosis, hypertension and the like can be precisely treated by targeted damaged myocardium pair multi-component drug combined delivery by using the natural homing effect of the platelet membrane, and the application has outstanding substantive features, optimal practical effect and higher economic value.

The invention discloses an application of a high mobility group protein B2 (HMGB2) in regeneration and repair of cardiac muscle after myocardial injury, and belongs to the technical field of biomedicine. Test results show that by overexpressing HMGB2 protein in myocardial cells, the in-vitro myocardial cell proliferation capacity is remarkably enhanced, and meanwhile, after acute myocardial ischemia injury in vivo, the myocardial cells can quickly start endogenous myocardial regeneration to play roles in promoting myocardial regeneration and repair, reducing scar formation, improving cardiac functions and the like. Besides, the invention designs a drug delivery mode based on a virus vector carrying HMGB2 gene, the problems of poor targeting, low biological safety, low treatment efficiency and the like of a traditional treatment method are solved, a new drug action target is provided for prevention and treatment of acute myocardial infarction and myocardial ischemia-reperfusion injury, and the drug delivery system has important clinical transformation value.

The invention discloses the use of Xinshubao tablets in preparing drugs for preventing and / or treating heart failure. Animal experiments prove that Xinshubao tablets can significantly prevent and treat heart failure by improving cardiac function and reducing cardiac fibrosis. Xinshubao tablets are applied to heart failure, especially to the prevention and treatment of heart failure with mildly reduced ejection fraction or heart failure with reduced ejection fraction, and have broad application prospects.

The invention relates to the field of biological medicines, and particularly discloses application of hydroxychloroquine in preparation of medicines for preventing and treating immune myocarditis, inflammatory cardiomyopathy and complications thereof. Immune myocarditis is caused by immune response caused by infectious or non-infectious diseases, and inflammatory cardiomyopathy is cardiomyopathy caused by chronic myocarditis. The hydroxychloroquine can reduce chemotaxis from inflammatory cells to the heart, inhibit macrophages from generating chemotactic factors CXCL16 and infiltration of Th17 cells, NKT cells and T lymphocytes, inhibit cardiac inflammatory response, fibrosis and cardiac function damage, and improve cardiac remodeling and ventricular dilatation. Hydroxychloroquine can significantly reduce cardiovascular composite endpoint events of patients with inflammatory cardiomyopathy, improve cardiac functions of the patients, and reduce hs-cTnI, NT-proBNP, hs-CRP and levels of various plasma inflammatory factors. Clinical and basic research results show that the hydroxychloroquine can be used for treating and / or preventing human immune myocarditis and inflammatory cardiomyopathy, and has the potential of being developed into the medicine for clinically preventing and treating immune myocarditis and inflammatory cardiomyopathy.

The invention relates to the technical field of pharmaceutical preparations, in particular to a traditional Chinese medicine compound and preparation for treating coronary heart disease and a preparation method and application of the traditional Chinese medicine compound and preparation. The traditional Chinese medicine composition is prepared from the following medicinal materials in parts by weight: 10-30 parts of astragalus membranaceus, 5-15 parts of rhodiola rosea, 10-30 parts of salvia miltiorrhiza, 5-15 parts of ligusticum wallichii, 10-30 parts of trichosanthes kirilowii maxim, 5-15 parts of allium macrostemon, 5-15 parts of folium ginkgo, 10-30 parts of radix puerariae, 10-30 parts of radix ophiopogonis, 3-10 parts of schisandra chinensis, 15-30 parts of oyster, 5-15 parts of cassia twig and 3-10 parts of liquorice. Animal experiment results show that the traditional Chinese medicine composition provided by the invention has remarkable and multi-aspect curative effect advantages in the aspect of treating a coronary heart disease rat model. The traditional Chinese medicine composition not only can enhance myocardial contractility and recover heart blood pumping function, but also can inhibit inflammatory response, relieve myocardial damage, effectively relieve myocardial structure damage and protect myocardial tissue integrity. In addition, a proportional experiment result shows that the effect of the composition provided by the invention can be obviously weakened by losing any medicine pair, so that all the medicines in the formula cannot be absent.

The application relates to application of miRNA and / or a miRNA agonist in preparation of a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, and belongs to the technical field of biological medicine. The medicine is administered through skeletal muscle injection, is secreted to a circulation system after expression on the skeletal muscle, is delivered to heart tissue by taking extracellular vesicles as carriers, and thus regulates myocardial cell functions. According to the animal model verification result, the miRNA can be delivered to the heart by the extracellular vesicles secreted by the skeletal muscle through injection of the medicine into the skeletal muscle, the expression level of the miRNA in the I / RI heart is significantly increased, the myocardial infarction area is effectively reduced, myocardial cell apoptosis is inhibited, myocardial fibrosis is reduced, and heart function is improved, a brand-new intervention strategy is provided for treatment of myocardial ischemia-reperfusion injury and related heart diseases, and a brand-new idea is opened up for research and development of heart failure treatment medicines.

The invention discloses an application of an HPCAL1 protein in enhancing a heart function. The invention finds that the HPCAL1 protein can be specifically combined with a recombinant beta3-adrenergic receptor and can be used as a beta3-adrenergic receptor antagonist protein; animal experiments find that by intravenous injection of a certain concentration of recombinant mouse HPCAL1 in an ischemia reperfusion mouse model, the mouse heart function can be effectively improved, and the ejection fraction of the mouse can be increased; therefore, the HPCAL1 protein can be used for enhancing the heart function and has a potential medicinal value for treating the heart function decline type cardiovascular diseases. The HPCAL1 protein is a biomacromolecule and is low in toxicity, so that the problem of high liver and kidney toxicity of chemical small molecule drugs is solved; and the method has a relatively high application value.

The invention discloses an application of radix pseudostellariae cyclic peptide B in antithrombotic drugs, and the radix pseudostellariae cyclic peptide B directly acts on vascular endothelial cells, promotes release of antithrombotic molecules such as nitric oxide and the like, and enhances vasodilatation and antithrombotic ability; the radix pseudostellariae cyclic peptide B can down-regulate expression of thrombus-related genes and reduce generation of thrombus-promoting factors such as inflammatory molecules, and the effects of the radix pseudostellariae cyclic peptide B in the aspects of improving heart functions, promoting angiogenesis and the like indicate that the radix pseudostellariae cyclic peptide B possibly has antithrombotic potential and shows positive effects in improving and preventing thrombus formation and the development process of thrombus. The possibility that the compound is used as a potential antithrombotic drug is strongly indicated, and a new research direction and hope are brought to the field of antithrombotic treatment.

The invention belongs to the technical field of medicines, and particularly relates to application of a CCNL1 inhibitor in preparation of a medicine for treating cardiomyopathy, and the amino acid sequence of CCNL1 is as shown in SEQ ID NO.1. It is found that by knocking down expression of CCNL1, DOX-induced myocardial cell apoptosis can be inhibited, DOX-induced myocardial cell ROS production can be inhibited, the lipid peroxidation level in DOX-induced myocardial cells can be reduced, and DOX-induced myocardial mitochondrial damage can be inhibited, so that application of the CCNL1 inhibitor in preparation of drugs for treating cardiomyopathy is provided.

The invention relates to the technical field of application of circRNADhx9 (circDhx9), particularly discloses application of circDhx9 as a molecular target in treatment of myocardial ischemia reperfusion injury, relates to application of circDhx9 as a molecular target in treatment of myocardial ischemia reperfusion injury, and belongs to the technical field of biological medicine. According to the invention, shRNA (short hairpin ribonucleic acid) capable of knocking down circDhx9 expression is designed, and an adeno-associated virus vector HBAAV2 / 9-circDhx9shRNA-EGFP (enhanced green fluorescent protein) of the shRNA is constructed. According to detection, circDhx9 is remarkably up-regulated in the heart after myocardial ischemia reperfusion, and the shRNA adeno-associated virus vector prepared by the invention can effectively reduce the expression quantity of circDhx9 in the heart of a mouse, so that the myocardial infarction area of the mouse after myocardial ischemia reperfusion is reduced, the heart function is improved, and the treatment of myocardial ischemia reperfusion injury by using circDhx9 is realized. The invention provides important supplement for biological functions of circDhx9, provides an effective treatment means for myocardial ischemia reperfusion injury, and also provides a theoretical basis for application of circDhx9 as a molecular target in treatment of myocardial ischemia reperfusion injury.

The invention discloses an application of a neuron-derived neurotrophic factor NDNF in promotion of regenerative repair and functional reconstruction of an injured heart, particularly relates to an application of the NDNF in a medicine for treating or improving the injured heart, a recombinant vector and a medicine, and belongs to the technical field of biological medicines. The invention provides application of NDNF in promotion of regenerative repair and functional reconstruction of damaged heart. The invention proves that the medicine prepared from the NDNF can be used for treating or improving the insufficiency and inflammation of the damaged heart, and particularly has a good treatment effect on the damaged heart caused by myocardial infarction, and the treatment effect specifically comprises the effect of reducing myocardial cell apoptosis and inflammation after myocardial infarction and the effect of inhibiting myocardial cell pathological hypertrophy after myocardial infarction due to overexpression of the NDNF. In addition, overexpression of the NDNF can also promote proliferation of myocardial cells after myocardial infarction.

The invention discloses an endocrinology department diabetes mellitus metabolism nursing massage device which comprises a binding structure and an elastic wearing structure made of skin-friendly fabric, and different wearing sizes can be adjusted according to different users. The massage structure is arranged on the binding structure in a sliding mode and can freely slide along the binding structure to adjust the position; through the design in the aspects of personalized adaptation, dynamic adjustment massage, oxygen supply increasing, precise positioning, multifunctional nursing and the like, dynamic adjustment of the oxygen supply amount is achieved, then the pressing frequency of a spring point pressing rod is dynamically adjusted, meanwhile, dynamic supply of the oxygen amount to a patient along with the movement frequency can be achieved, and the patient is more comfortable. The traditional Chinese medicine composition can better meet the exercise requirements of diabetic patients, can promote body metabolism, control blood sugar and improve insulin sensitivity, is beneficial to cardiovascular systems, can improve psychological states and is beneficial to diabetes management.

Provided is a valve implantation device with the assistance of a heart isolation device, which includes a valve, a heart isolation device, and a valve connection device, wherein the heart isolation device includes an isolation device body; the isolation device body is provided with a positioning part; the isolation device body is fixed on a heart tissue through the positioning part; the valve connection device includes a first connection part; one side of the first connection part is connected with the valve; the isolation device body is provided with a second connection part; and the first connection part and the second connection part are connected during use. The device of the present disclosure can improve the cardiac function before / during valve implantation and increases the effectiveness of an operation. Fixing the valve by the hook-type structure can reduce metal objects required for replacement and avoid potential injury to a heart valve structure. A connector structure connected to the valve stably locates the valve and accurately releases the height of the valve, so that paravalvular leak and injury to a valve annulus plane can be prevented.

The invention provides application of a Xinsunning preparation in preparation of a medicine for preventing and treating heart failure, and relates to the technical field of traditional Chinese medicine, the Xinsunning preparation can obviously improve the heart function, and the Xinsunning preparation can be applied in preparation of the medicine for preventing and treating heart failure by improving the heart function.

A surgical annulus, a mechanical valve, and a surgical biovalve are disclosed. The three cardiac surgical valve instruments preferably adopt a high valve ring or short valve angle design. By means of the high-valve-ring surgical valve ring, left ventricular outflow tract obstruction can be avoided during a mitral valve intervention operation in the future. A mechanical valve and a surgical bioprosthetic valve move up a leaflet fixing structure and leaflets through a high annulus or short valve angle design to retain leaflets and subvalvular structures as much as possible in future mitral and tricuspid valve operations to facilitate post-operative heart function improvement.